Literature DB >> 11001080

Lower airway bacterial colonization in asymptomatic smokers and smokers with chronic bronchitis and recurrent exacerbations.

I Qvarfordt1, G C Riise, B A Andersson, S Larsson.   

Abstract

Bacterial colonization of the lower airways in patients with chronic bronchitis (CB) has been described mainly in patients with co-existing chronic obstructive pulmonary disease (COPD). Although smoking has been identified as a risk factor for bacterial colonization it is not known whether asymptomatic smokers (AS) can be colonized. The aim of this study was to study lower airway bacterial colonization in smokers with stable CB and recurrent exacerbations and compare with AS and healthy never-smokers (NS). Thirty-nine smokers with CB and recurrent exacerbations (median FEV1 85% of predicted normal), 10 AS and 10 NS, underwent bronchoscopy and a two-step bronchoalveolar lavage (BAL) procedure where the first portion (20 ml, 'pre-BAL') was recovered separately from the rest (140 ml, 'BAL'). The degree of oropharyngeal contamination of pre-BAL and BAL samples was evaluated by cytology. Semiquantitative bacterial cultures were performed on all samples. Higher bacterial numbers than 10(3) colony-forming units (cfu) x ml(-1) in BAL were found only in the two smoking groups. Using 10(3) cfu x ml(-1) as cut-off, 6/10 (60%) in the AS-, and 7/35 (20%) in the CB-group were colonized in the lower airways. In all, 29% of all smokers had bacterial colonization. Only bacteria belonging to the normal oropharyngeal flora were found. The proportion of samples with oropharyngeal contamination was significantly lower in BAL than in pre-BAL (5% vs. 21%, P=0.039). The proportion of sterile samples was significantly higher in BAL than in pre-BAL (49% vs. 26%, P=0.002). Lower airway bacterial colonization was found both in asymptomatic smokers and in patients with CB. Colonization with potential respiratory pathogens is uncommon in patients with CB and recurrent exacerbations without severe airflow obstruction. The two-step BAL procedure seems to decrease oropharyngeal contamination.

Entities:  

Mesh:

Year:  2000        PMID: 11001080     DOI: 10.1053/rmed.2000.0857

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  6 in total

1.  Topographical continuity of bacterial populations in the healthy human respiratory tract.

Authors:  Emily S Charlson; Kyle Bittinger; Andrew R Haas; Ayannah S Fitzgerald; Ian Frank; Anjana Yadav; Frederic D Bushman; Ronald G Collman
Journal:  Am J Respir Crit Care Med       Date:  2011-06-16       Impact factor: 21.405

2.  Airway epithelial expression of TLR5 is downregulated in healthy smokers and smokers with chronic obstructive pulmonary disease.

Authors:  Rui Wang; Joumana Ahmed; Guoqing Wang; Ibrahim Hassan; Yael Strulovici-Barel; Jacqueline Salit; Jason G Mezey; Ronald G Crystal
Journal:  J Immunol       Date:  2012-08-01       Impact factor: 5.422

3.  Impact of tobacco smoke on interleukin-16 protein in human airways, lymphoid tissue and T lymphocytes.

Authors:  A Andersson; I Qvarfordt; M Laan; M Sjostrand; C Malmhall; G C Riise; L-O Cardell; A Linden
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

4.  Autoantibodies in patients with chronic obstructive pulmonary disease.

Authors:  Carol A Feghali-Bostwick; Aneal S Gadgil; Leo E Otterbein; Joseph M Pilewski; Michael W Stoner; Eva Csizmadia; Yingze Zhang; Frank C Sciurba; Steven R Duncan
Journal:  Am J Respir Crit Care Med       Date:  2007-11-01       Impact factor: 21.405

5.  Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke.

Authors:  Ruth E MacRedmond; Catherine M Greene; Delbert R Dorscheid; Noel G McElvaney; Shane J O'Neill
Journal:  Respir Res       Date:  2007-11-22

6.  No development of ciprofloxacin resistance in the Haemophilus species associated with pneumonia over a 10-year study.

Authors:  Josef Yayan; Beniam Ghebremedhin; Kurt Rasche
Journal:  BMC Infect Dis       Date:  2015-11-13       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.